Mouse TIGIT (Vstm3) Antibody from BIOLEGEND

TIGIT (T cell immunoreceptor with Ig and ITIM domains precursor) contains an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif. TIGIT is an inhibitory receptor expressed on the surface of natural killer (NK) cells. TIGIT recognizes nectin and nectin-like adhesion molecules and thus plays a critical role in the innate immune response to malignant transformation. TIGIT in conjunction with CD226 forms a pathway that has prominent similarities to the costimulatory CD28/CTLA-4 pathway. CD226 and TIGIT bind the same set of ligands (CD155 and CD112) and CD226 is a positive regulator of T cell responses, while TIGIT inhibits them. Knockdown of TIGIT expression in human CD4⁺ T cells results in an increase of both T-bet and IFN-γ mRNA and protein expression. These effects are overcome by blocking CD226 signaling indicating that TIGIT exerts immunosuppressive effects by competing with CD226 for the same ligand, CD155. The binding of CD155 to TIGIT on human dendritic cells enhances the production of interleukin 10 and diminishes the production of interleukin 12p40. TIGIT shows an inhibitory effect on cell-signaling pathway in murine models of experimental autoimmune encephalomyelitis (EAE). Loss of TIGIT expression in mice results in hyperproliferative T cell responses and increased susceptibility to EAE.